Decreasing pancreatic toxicity of tacrolimus by dosage reduction.
Uchida
K
K
Department of Transplant Surgery, Nagoya Daini Red Cross Hospital, Japan.
Tominaga
Y
Y
Haba
T
T
Katayama
A
A
Ichimori
T
T
Yamada
K
K
Hibi
Y
Y
Uemura
O
O
Morozumi
K
K
Takagi
H
H
D000284:Administration, Oral; D001786:Blood Glucose / Q000378:metabolism; D003920:Diabetes Mellitus / Q000139:chemically induced* / Q000517:prevention & control; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D018149:Glucose Intolerance / Q000139:chemically induced* / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D016030:Kidney Transplantation / Q000276:immunology*; D008657:Metabolic Clearance Rate; D011239:Prednisolone / Q000627:therapeutic use; D012044:Regression Analysis; D016559:Tacrolimus / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics
D001786:Blood Glucose; D007166:Immunosuppressive Agents; D011239:Prednisolone; D016559:Tacrolimus